Division of Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Via Albertoni - 15, Bologna, Italia.
Immunotherapy. 2021 Jun;13(8):637-644. doi: 10.2217/imt-2021-0026. Epub 2021 Apr 6.
Advanced hepatocellular carcinoma (HCC) patients present poor prognosis. However, recent years have seen the advent of several novel treatments in this setting, where the role of immune checkpoint inhibitors has been investigated. Among these, the PD-L1 inhibitor atezolizumab in combination with bevacizumab has reported unprecedented results in treatment-naive patients with unresectable disease, with the recently published IMbrave150 Phase III trial showing the superiority of the combination over sorafenib monotherapy, and after having attended more than a decade of 'stagnation', the HCC medical community has a new standard of care. Herein, we examine the development and the impact of atezolizumab in advanced HCC, summarizing the mechanism of action, pharmacokinetics and recent evidence from Phase I to III clinical trials.
晚期肝细胞癌（HCC）患者预后较差。然而，近年来，这一领域出现了几种新的治疗方法，其中包括免疫检查点抑制剂的作用。在这些方法中，PD-L1 抑制剂阿替利珠单抗联合贝伐珠单抗在未经治疗的不可切除疾病患者中报告了前所未有的结果，最近发表的 IMbrave150 期 III 期试验显示该联合治疗优于索拉非尼单药治疗，在经历了十多年的“停滞”之后，HCC 医学界有了新的治疗标准。在此，我们研究了阿替利珠单抗在晚期 HCC 中的发展和影响，总结了其作用机制、药代动力学和从 I 期到 III 期临床试验的最新证据。
